Is Longevity Becoming the Next Global Race? | Longevity News Roundup — Week 29, 2026
Notes de l’épisode
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
----------
Sponsor: FlexBeam
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.
Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.
Link: rechargehealthas.sjv.io/jRQyQ5
----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy.
- BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.
- Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.
- Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.
- Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.
- Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.
- US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine.
----------
News & References:
- BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/
- Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/
- Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/
- When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/
- Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/
- US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/